Exclusive Summary

• - DR tablets are first-line antifungal prophylaxis in high-risk hematology/HSCT patients with strong guideline endorsement and superiority over oral suspension.
• - Registered in the US, Australia, Singapore, Canada, and GCC with US-FDA GMP, enabling fast market access and tender readiness.
• - Global demand is steady and non-discretionary: ~100–150k AML cases and ~90–100k HSCT per year, most requiring 4–6 weeks’ prophylaxis.
• - 10+ generic holders exist in the US and more globally, typically pricing 60–85% below originator and driving substantial course-of-therapy savings.
• - 100 mg enteric-coated (delayed-release) tablets offer more reliable exposure and adherence, ideal for rapid hospital-channel distribution partnerships.